Global Trends In R&D 2024: Activity, Productivity, And Enablers

Biomedical breakthroughs are revolutionizing healthcare on a global scale. The collaborative ecosystem driving this progress has faced significant challenges amid the COVID-19 pandemic but is now regrouping and focusing on future opportunities to enhance our understanding of human biology and disease, discover novel therapeutics, and demonstrate the clinical value of these innovations for individuals, populations, and healthcare systems.

Across various metrics such as funding levels, trial initiations, drug launches, and R&D success rates, it's evident that both industry and investors continue to recognize the immense value of ongoing research efforts worldwide.

This report evaluates trends in new drug launches and the overall number of clinical trials initiated, while also delving into the landscape of R&D funding and the activities of diverse companies. It introduces a Clinical Development Productivity Index to compare research outcomes with input efforts. Furthermore, it explores the remarkable agility and progress of the innovation ecosystem, analyzing factors like trial duration reduction and shifts in clinical development timelines, which vary across different diseases.